These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 34262571)

  • 1. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
    Park HE; Lee W; Shin MK; Shin SJ
    Front Immunol; 2021; 12():703060. PubMed ID: 34262571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
    Hawn TR; Shah JA; Kalman D
    Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
    Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
    mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
    Abreu R; Giri P; Quinn F
    Front Immunol; 2020; 11():1553. PubMed ID: 32849525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding Metabolic Regulation Between Host and Pathogens: New Opportunities for the Development of Improved Therapeutic Strategies Against
    Park JH; Shim D; Kim KES; Lee W; Shin SJ
    Front Cell Infect Microbiol; 2021; 11():635335. PubMed ID: 33796480
    [No Abstract]   [Full Text] [Related]  

  • 9. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.
    Kim H; Shin SJ
    Cell Mol Life Sci; 2023 Sep; 80(10):291. PubMed ID: 37704889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4404-17. PubMed ID: 24245765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural and trained innate immunity against Mycobacterium tuberculosis.
    Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
    Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLR2 is non-redundant in the population and subpopulation responses to
    Jani C; Solomon SL; Peters JM; Pringle SC; Hinman AE; Boucau J; Bryson BD; Barczak AK
    mSystems; 2023 Aug; 8(4):e0005223. PubMed ID: 37439558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic host-directed strategies to improve outcome in tuberculosis.
    Young C; Walzl G; Du Plessis N
    Mucosal Immunol; 2020 Mar; 13(2):190-204. PubMed ID: 31772320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis.
    Chai Q; Wang L; Liu CH; Ge B
    Cell Mol Immunol; 2020 Sep; 17(9):901-913. PubMed ID: 32728204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment.
    Gopalaswamy R; Shanmugam S; Mondal R; Subbian S
    J Biomed Sci; 2020 Jun; 27(1):74. PubMed ID: 32552732
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Petruccioli E; Petrone L; Chiacchio T; Farroni C; Cuzzi G; Navarra A; Vanini V; Massafra U; Lo Pizzo M; Guggino G; Caccamo N; Cantini F; Palmieri F; Goletti D
    Front Immunol; 2021; 12():716857. PubMed ID: 34447382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Management of Drug-resistant Mycobacterium tuberculosis Strains: Pathogen-targeted Versus Host-directed Treatment Approaches.
    Al-Ghafli H; Al-Hajoj S
    Curr Pharm Biotechnol; 2019; 20(4):272-284. PubMed ID: 30062961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host-Directed Therapeutics as a Novel Approach for Tuberculosis Treatment.
    Kim YR; Yang CS
    J Microbiol Biotechnol; 2017 Sep; 27(9):1549-1558. PubMed ID: 28683527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.